Compugen (CGEN) Cash & Equivalents (2009 - 2026)

Compugen (CGEN) has 18 years of Cash & Equivalents data on file, last reported at $12.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 14.68% year-over-year to $12.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.4 million (down 14.68% YoY), and the FY2025 full-year result was $90.6 million, up 396.99% from the prior year.
• Cash & Equivalents retreated to $12.4 million in Q1 2026, from $90.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $106.8 million in Q1 2022 to a low of $362000.0 in Q4 2022.
• A 5-year average of $35.0 million and a median of $14.6 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 95.36% in 2022 and surged 3737.02% in 2023, its largest moves.
• Tracing CGEN's Cash & Equivalents over 5 years: stood at $362000.0 in 2022, then surged by 3737.02% to $13.9 million in 2023, then soared by 31.24% to $18.2 million in 2024, then soared by 396.99% to $90.6 million in 2025, then tumbled by 86.27% to $12.4 million in 2026.
• Business Quant data shows CGEN's Cash & Equivalents at $12.4 million in Q1 2026, $90.6 million in Q4 2025, and $7.5 million in Q3 2025.